Sirion Therapeutics, Inc.

Sirion Therapeutics, Inc. logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
2005-01-01
Employees
101
Market Cap
-
Website
https://www.siriontherapeutics.com
Clinical Trials
Related News

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)

Phase 3
Completed
Conditions
Inflammation
Interventions
Other: Placebo
Drug: Difluprednate
First Posted Date
2008-02-15
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616993
Locations
🇺🇸

Eye Associates of Fort Myers, Fort Myers, Florida, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Difluprednate
Other: Placebo
First Posted Date
2008-02-15
Last Posted Date
2011-06-30
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
120
Registration Number
NCT00616070
Locations
🇺🇸

Charlotte Eye, Ear, Nose & Throat, Charlotte, North Carolina, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-10-25
Last Posted Date
2007-10-25
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00549289
Locations
🇺🇸

Clayton Eye Center, Morrow, Georgia, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-10-23
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00548301
Locations
🇺🇸

Eye Center Northeast, Bangor, Maine, United States

Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

Phase 3
Completed
Conditions
Dry Eye Syndromes
First Posted Date
2007-07-17
Last Posted Date
2011-07-01
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00502073
Locations
🇺🇸

Eye Center Northeast, Bangor, Maine, United States

Study of Difluprednate in the Treatment of Uveitis

Phase 3
Completed
Conditions
Uveitis
First Posted Date
2007-07-16
Last Posted Date
2008-08-29
Lead Sponsor
Sirion Therapeutics, Inc.
Registration Number
NCT00501579
Locations
🇺🇸

John-Kenyon American Eye Institute, New Albany, Indiana, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Placebo
Drug: Difluprednate
First Posted Date
2007-02-01
Last Posted Date
2009-07-02
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
219
Registration Number
NCT00430092
Locations
🇺🇸

Comprehensive Eye Care, Washington, Missouri, United States

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)

Phase 3
Completed
Conditions
Inflammation
Interventions
Drug: Difluprednate
Drug: Placebo
First Posted Date
2007-02-01
Last Posted Date
2009-07-02
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
219
Registration Number
NCT00429923
Locations
🇺🇸

Comprehensive Eye Care, Washington, Missouri, United States

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

First Posted Date
2007-02-01
Last Posted Date
2010-06-22
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
245
Registration Number
NCT00429936

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation

Phase 2
Completed
Conditions
Inflammation
First Posted Date
2006-12-04
Last Posted Date
2006-12-06
Lead Sponsor
Sirion Therapeutics, Inc.
Target Recruit Count
24
Registration Number
NCT00407225
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy